Amsterdam, The Netherlands, November 8, 2018 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces that it has appointed three new senior team members to further strengthen the Company as it transitions into commercial stage. Mr. Dirk De Naeyer has been appointed Head of Supply Chain, Mr. Jonathan Sweeting has been appointed Head of Commercial Europe and Mr. Marcel Zwaal has been appointed Head of Corporate Development.
Arthur Lahr, CEO of Kiadis Pharma, commented: "I am delighted to welcome Dirk De Naeyer, Jonathan Sweeting and Marcel Zwaal to Kiadis. Building a biotech company requires highly experienced people across all disciplines. With Dirk, Jonathan and Marcel joining our team we have succeeded in attracting yet more highly experienced international talents to develop and commercialize ATIR101 and build out Kiadis. These appointments confirm our ability to attract seasoned senior executives to deliver on our strategy."
Mr. Dirk De Naeyer joins Kiadis Pharma as Head of Supply Chain from Janssen Pharmaceuticals where he spent 14 years in various leadership positions. Most recently, he was co-lead for the integration of Actelion into Janssen. Prior to that, he was the head of the Janssen Global Clinical Operations team and held multiple supply chain and operations leadership positions. This included heading up the Janssen Clinical Supply Chain, overseeing all active pharmaceutical ingredient (API) and Drug Product manufacturing, Packaging and Distribution for Janssen R&D, which covered Small Molecules, Biologics and Stem Cell therapies. Mr. De Naeyer joined Janssen after five years at McKinsey. He holds a degree in Engineering from the KU Leuven, Belgium, and an MBA from the University of Chicago. Mr. De Naeyer is a Belgian citizen.
Mr. Jonathan Sweeting joins Kiadis Pharma as Head of Commercial Europe. Prior to this he spent over five years at GSK in various leadership positions, most recently as Senior Vice President and Head of the Global Respiratory Franchise and previously in roles as General Manager Poland and Global Commercialization Leader for Respiratory Biologics. Mr. Sweeting joined GSK from AstraZeneca where he spent over eight years in global and local roles in the UK and Russia. Prior to that he was at Accenture for five years. Mr. Sweeting holds an MA (Hons) degree in Chemistry from the University of Cambridge and an MBA from INSEAD. Mr. Sweeting is a British citizen.
Mr. Marcel Zwaal joins Kiadis Pharma as Head of Corporate Development from his previous role as CEO of Hubrecht Organoid Technologies. Before that Marcel worked in Corporate Development at Galapagos, served as CEO of cell therapy biotech startup DCPrime and held several senior management positions at Crucell in finance and business development prior to its acquisition by Johnson & Johnson in 2011. Mr. Zwaal has over 20 years' experience in finance and business, 10 years of which has focused on medical innovation and biotechnology. He holds an Executive Master of Finance and Control degree and a Finance BA Master's degree from Vrije Universiteit Amsterdam. Mr. Zwaal is a Dutch citizen.